MedStar Georgetown University Hospital: Patients Can Now Benefit from Same-day Procedure to Diagnose and Treat Lung Cancer

Georgetown University Hospital: Imagine being diagnosed with lung cancer and having the tumor surgically removed on the same day, thereby increasing the opportunity for limited follow-up therapy – or even curing the cancer.

A team of pulmonary and thoracic experts at MedStar Georgetown University Hospital are the first in the region to combine these two steps, thus saving precious time for patients in addressing the “beast of all cancers,” according to Eric D. Anderson, MD, director of Interventional Pulmonology at MedStar Georgetown University Hospital.

“Coupling this early diagnosis with same-day surgery for lung cancer is a win for patients,” said Dr. Anderson. “Given the impact of lung cancer – the leading cause of cancer deaths — this is a major step towards stopping the disease in its tracks, resulting in better outcomes and giving patients an improved chance at life.”

In this new approach – Combined Robotic Assisted Thoracic Surgery (CRATS) – high-risk lung cancer patients first undergo a low dose CT scan of the lung to monitor for tumors. If a tumor is detected, the Ion robot bronchoscope is used to biopsy the lung tumor. If the lung tumor is found – through real-time biopsy – to be cancer, then the endobronchial ultrasound is used to determine if the cancer has spread to lymph nodes. If the lymph nodes are normal, then the patient undergoes surgery to remove the portion of the lung with the cancerous tumor using the DaVinci robotic video-assisted thoracic surgery system during the same anesthesia procedure. This new process – diagnosing lung cancer and removing the tumor at the same time — saves valuable time by removing the cancer right when it is detected, thereby limiting the opportunity for spread of disease and allowing for the start of additional therapies sooner if needed. In some instances, this approach can be curative of the cancer.

“Millimeters matter,” says Dr. Anderson. “We know that the earlier we find the nodule in the lung and the smaller it is, that has the greatest impact on mortality. If we find the nodule at 1 mm, there is 90% chance of survival. At 2 mm, there is 80%, and at 3 mm 70%. Combine those odds with the potential immediate removal of the tumor, and the Ion robot gives patients a real chance for better outcomes.”

Previously this process of diagnosis and treatment could take several weeks — a critical time when cancer can continue to grow, and patients can experience increased anxiety about their health and prognosis.

“This combined therapy of diagnosis and surgical removal of the tumor at the same time offers new hope for patients with lung cancer,” said Dr. Marc Margolis, Chief of Robotic Thoracic Surgery at Medstar Georgetown University Hospital, “Removing a cancerous tumor in the lung, when possible, is key to advancing the opportunity for improved outcomes for these patients. The earlier we can remove the cancer, the sooner we can help our patients with any additional therapies they may need to move forward with their life.”

Wayne Norris, 67, had the low dose CT lung screen that indicated a tumor. He was immediately scheduled for the combined procedure in the event the tumor was cancer.

“We feel blessed not to have had to wait for biopsy and to schedule surgery. It was a relief to get this all taken care of at one time and get the cancer out,” said Norris, whose tumor was diagnosed as cancer and removed immediately.


Ion Robot: MedStar Georgetown University Hospital is the first and only hospital in the region to have the Ion robot — a “game-changing” tool according to Dr. Anderson, that enables surgeons to reach peripheral nodules in the lung to diagnose lung cancer sooner, thereby increasing the opportunity for earlier diagnosis and treatment of lung cancer, the leading cause of cancer deaths worldwide for both men and women.

Ion endoluminal is a minimally invasive robotic-assisted system that helps address a challenging aspect of lung biopsy by enabling physicians to obtain tissue samples from deep within the lung.

While survival rates for lung cancer have improved over the past decade in part due to early screening, physicians know that improved outcomes are directly linked to early detection. Coupled with regular screening for those at high risk, the Ion system makes possible earlier and more accurate detection of cancer, especially for small nodules.

In addition to giving surgeons real-time guidance for improved accuracy, the Ion robot can navigate through small and tortuous airways to reach nodules in any airway segment within the lung with its flexible biopsy needle that can pass through very tight bends to collect tissue in the peripheral lung. The catheter’s 2 mm working channel can also accommodate other biopsy tools, such as biopsy forceps and cytology brushes, if necessary. The system’s fiber-optic shape sensor technology, developed by Intuitive, is to provide the physician with the precise location and shape information of the catheter throughout the navigation and biopsy process.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”